Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results for the second quarter ended June 30, 2015. The call can be accessed by dialing 1-866-428-2694

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 30, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17thWorld Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 11, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 3, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today. Consistent with the Company’s goal of streamlining operations to align with its needs going forward, the new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with no laboratory

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 20, 2015– AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American